Navigation Links
Breathable treatment to help prevent asthma attacks

Details of a treatment that could help asthmatics fight infections that trigger 80% of asthma attacks, developed by University of Southampton spin-out company Synairgen, will be presented to European respiratory experts on Sunday 2 September.

The study provides the first evidence that boosting asthmatics' immune systems can help reduce the number of asthma attacks due to the common cold and other viral infections for the 5.4 million asthmatics in the UK.

Professor Ratko Djukanovic, a respiratory specialist at the University of Southampton and Southampton General Hospital, led the study and will present findings to the European Respiratory Society's annual congress in Vienna.

He says: "We have demonstrated the potential of a treatment, simply breathed in by the patient, which significantly reduces worsening of asthma symptoms and the patient's need to use their asthma inhaler in response to common cold infection. By presenting an immune system protein molecule, interferon beta, to the patient's lungs we can prime their body to challenge infections more effectively."

Professor Djukanovic directs the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Unit, one of 20 sites involved in the trial and a partnership between the University of Southampton and University Hospital Southampton NHS Foundation Trust, funded by NIHR.

He continues: "Southampton researchers, working alongside asthma patients, made the original discovery that weakened immunity amongst asthmatics was key to viral impacts; now study participants are helping us to confirm that discovery and translate it into treatments for their, and other asthmatic patients', benefit through the work of the unit."

Professor Stephen Holgate CBE, leading international asthma specialist at the University of Southampton and founder of Synairgen, says: "This is a really promising breakthrough for the future treatment of asthma and one of the most exciting developments that I have seen in years. These impressive findings across different endpoints, together with the accumulating body of evidence we have generated for other respiratory viruses such as influenza (Swine and Bird flu) and respiratory syncytial virus (RSV), strongly suggest that inhaled interferon beta has the potential to be used as a powerful broad spectrum antiviral respiratory drug in lung diseases such as COPD and pandemic flu."

Richard Marsden, Chief Executive of Synairgen, adds: "This is a great result for the development of our programme. To put this treatment's potential into context, it is estimated that in the US alone there are some 2 to 4 million difficult to treat (Step 4 and 5) adult asthma sufferers who could benefit from this therapy. We continue to analyse the wealth of data generated by this important trial and to plan the next phase of its development, ideally alongside an industry partner."


Contact: Becky Attwood
University of Southampton

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
Breaking Medicine Technology: